212 related articles for article (PubMed ID: 20723926)
1. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.
Smith MR; Morton RA; Barnette KG; Sieber PR; Malkowicz SB; Rodriguez D; Hancock ML; Steiner MS
J Urol; 2010 Oct; 184(4):1316-21. PubMed ID: 20723926
[TBL] [Abstract][Full Text] [Related]
2. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.
Smith MR; Morton RA; Barnette KG; Sieber PR; Malkowicz SB; Rodriguez D; Hancock ML; Steiner MS
J Urol; 2013 Jan; 189(1 Suppl):S45-50. PubMed ID: 23234631
[TBL] [Abstract][Full Text] [Related]
3. Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer.
Smith MR; Malkowicz SB; Brawer MK; Hancock ML; Morton RA; Steiner MS
J Urol; 2011 Dec; 186(6):2239-44. PubMed ID: 22014807
[TBL] [Abstract][Full Text] [Related]
4. Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer.
Morgans AK; Hancock ML; Barnette KG; Steiner MS; Morton RA; Smith MR
J Urol; 2012 Mar; 187(3):889-93. PubMed ID: 22245322
[TBL] [Abstract][Full Text] [Related]
5. Denosumab in men receiving androgen-deprivation therapy for prostate cancer.
Smith MR; Egerdie B; Hernández Toriz N; Feldman R; Tammela TL; Saad F; Heracek J; Szwedowski M; Ke C; Kupic A; Leder BZ; Goessl C;
N Engl J Med; 2009 Aug; 361(8):745-55. PubMed ID: 19671656
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer.
Saylor PJ; Morton RA; Hancock ML; Barnette KG; Steiner MS; Smith MR
J Urol; 2011 Aug; 186(2):482-6. PubMed ID: 21679977
[TBL] [Abstract][Full Text] [Related]
7. Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study.
Smith MR; Malkowicz SB; Chu F; Forrest J; Sieber P; Barnette KG; Rodriquez D; Steiner MS
J Clin Oncol; 2008 Apr; 26(11):1824-9. PubMed ID: 18398147
[TBL] [Abstract][Full Text] [Related]
8. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study.
Smith MR; Malkowicz SB; Chu F; Forrest J; Price D; Sieber P; Barnette KG; Rodriguez D; Steiner MS
J Urol; 2008 Jan; 179(1):152-5. PubMed ID: 18001802
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer: Reducing fracture risk in men on androgen deprivation therapy.
Shahinian VB
Nat Rev Urol; 2011 Jan; 8(1):9-10. PubMed ID: 21135877
[No Abstract] [Full Text] [Related]
10. [Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].
Kudlacek S; Puntus T
Wien Med Wochenschr; 2012 Sep; 162(17-18):380-5. PubMed ID: 22875632
[TBL] [Abstract][Full Text] [Related]
11. Re: Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. M. R. Smith, R. A. Morton, K. G. Barnette, P. R. Sieber, S. B. Malkowicz, D. Rodriguez, M. L. Hancock and M. S. Steiner. J Urol 2010;184:1316-1321.
Langley RE; Cafferty FH; Pollock PA; Price P; Abel PD
J Urol; 2011 Jun; 185(6):2430-1; author reply 2431-2. PubMed ID: 21513954
[No Abstract] [Full Text] [Related]
12. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial.
Greenspan SL; Nelson JB; Trump DL; Resnick NM
Ann Intern Med; 2007 Mar; 146(6):416-24. PubMed ID: 17371886
[TBL] [Abstract][Full Text] [Related]
13. Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Alibhai SMH; Zukotynski K; Walker-Dilks C; Emmenegger U; Finelli A; Morgan SC; Hotte SJ; Tomlinson GA; Winquist E
Ann Intern Med; 2017 Sep; 167(5):341-350. PubMed ID: 28785760
[TBL] [Abstract][Full Text] [Related]
14. Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy.
Taneja SS; Smith MR; Dalton JT; Raghow S; Barnette G; Steiner M; Veverka KA
Expert Opin Investig Drugs; 2006 Mar; 15(3):293-305. PubMed ID: 16503765
[TBL] [Abstract][Full Text] [Related]
15. Management of osteoporosis in men on androgen deprivation therapy.
Adler RA
Maturitas; 2011 Feb; 68(2):143-7. PubMed ID: 21129866
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
Choo R; Lukka H; Cheung P; Corbett T; Briones-Urbina R; Vieth R; Ehrlich L; Kiss A; Danjoux C
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1239-45. PubMed ID: 23265571
[TBL] [Abstract][Full Text] [Related]
17. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
[TBL] [Abstract][Full Text] [Related]
18. Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer.
Egerdie RB; Saad F; Smith MR; Tammela TL; Heracek J; Sieber P; Ke C; Leder B; Dansey R; Goessl C
Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):308-12. PubMed ID: 22641239
[TBL] [Abstract][Full Text] [Related]
19. Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer.
Denham JW; Nowitz M; Joseph D; Duchesne G; Spry NA; Lamb DS; Matthews J; Turner S; Atkinson C; Tai KH; Gogna NK; Kenny L; Diamond T; Smart R; Rowan D; Moscato P; Vimieiro R; Woodfield R; Lynch K; Delahunt B; Murray J; D'Este C; McElduff P; Steigler A; Kautto A; Ball J
BJU Int; 2014 Sep; 114(3):344-53. PubMed ID: 24512527
[TBL] [Abstract][Full Text] [Related]
20. Androgen deprivation in prostate cancer and the long-term risk of fracture.
Ojeda S; Lloret M; Naranjo A; Déniz F; Chesa N; Domínguez C; Lara PC
Actas Urol Esp; 2017 Oct; 41(8):491-496. PubMed ID: 28259363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
